Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep

CNYX-005Positive

AI Analysis

Summary

Carnyx Therapeutics unveiled preclinical data for oral sleep candidate CNYX-005 showing a 1.5- to 2-hour increase in total NREM sleep time and appointed Chris Brearley, M.D., as Chief Medical Officer as the company advances toward clinical development.

Outcome Details

Preclinical data showing 1.5- to 2-hour increase in total NREM sleep

Importance:4/10

Sentiment:

0.60

Preclinical dataSleep disorderOral candidateChief Medical Officer appointmentClinical development

Related Companies

$MDCE

Read the original article

Published by PR Newswire Biotech on October 14, 2026 10:00 AM

Read Original